Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

• US 7,358,086 B2
• Filed: 07/21/2004
• Issued: 04/15/2008
• Est. Priority Date: 10/13/2000
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Tetsu, Osamu, McCormick, Frank, Wakita, Kenichi
• Primary Examiner(s): KETTER, JAMES S
• Application Number:
  US10/896,600
• Publication Number:
  US 20040265791A1
• Time in Patent Office: 1,364 Days
• Field of Search: 435/325, 435/7.2
• US Class Current: 435/367
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0058 Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/1055 Protein x Protein interaction, e.g. two hybrid selection
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: C12Q 2565/201 Two hybrid system

Abstract

This invention utilizes a two-hybrid system to screen for agents that modulate the ability of a cell to degrade or to accumulate a metabolic product or to selective kill a cell or to selectively express a gene or cDNA in a cell that has a defect in its ability to degrade or to accumulate a metabolic product. One embodiment provides a mammalian cell comprising a nucleic acid encoding a peptide binding domain and an effector gene; a first chimeric protein comprising a nucleic acid binding domain that binds the peptide binding domain attached to the metabolic product or to a ligand that binds to the metabolic product; and a second chimeric protein comprising an expression control protein attached to the metabolic product or to the ligand that binds to the metabolic product such that when the first chimeric protein comprises the metabolic product, the second chimeric protein comprises the ligand and when the first chimeric protein comprises the ligand, the second chimeric protein comprises the metabolic product. The cell is contacted with a test agent and an alteration of expression of the effector gene is detected (if present) where a change in expression of the effector gene in response to the test agent indicates that the test agent modulates the ability of the cell to accumulate or degrade the metabolic product.

Claims

1. A cell comprising:

an accumulation or degradation of a metabolic product;

a nucleic acid encoding a peptide binding site and an effector gene;

a first chimeric protein comprising a nucleic acid binding protein that binds said peptide binding site where said nucleic acid binding protein is attached to said metabolic product or to a ligand that binds to said metabolic product; and

a second chimeric protein comprising an expression control protein attached to said metabolic product or to said ligand that binds to said metabolic product such that when said first chimeric protein comprises said metabolic product, said second chimeric protein comprises said ligand and when said first chimeric protein comprises said ligand, said second chimeric protein comprises said metabolic product;

wherein said cell is a cell selected from the group consisting of SW480, SW48, DLD-1, HCT-116,HT29, 293, U-20S, T-47D, MCF-7, HeLa, A549, Hep G2, a mammalian cell, and a Jarkat cell.

2. The cell of claim 1, wherein said expression control protein is a transactivator.

3. The cell of claim 2, wherein said transactivator is VP16.

5. The cell of claim 1, wherein said nucleic acid binding protein is selected from the group consisting of GAL-4, and GAL-4-Y.

6. The cell of claim 1, wherein said effector is selected from the group consisting of a reporter gene, a cytotoxin, and an apoptosis-inducing gene.

7. The cell of claim 1, wherein said reporter gene is selected from the group consisting of:

chloramphenicol acetyl transferase (CAT), luciferase, b-galactosidase (b-gal), alkaline phosphatase, horse radish peroxidase (HRP), growth hormone (GH), and green fluorescent protein (GFP).

8. The cell of claim 1, wherein said effector encodes a cytotoxin selected from the group consisting of thymidine kinase, pseudomonas exotoxin, diphtheria toxin, ricin, and abrin.

9. The cell of claim 6, wherein said apoptosis-inducing gene is selected from the group consisting of P53, P73, Bax, Bad, FADD, and a caspase.

10. The cell of claim 1, wherein said ligand and said metabolic product respectively are selected from the group consisting of beta-catenin and a Tcf, a NF-kB and I-kB, a P53 and MDM2, a receptor and its heteromelic receptor partner.

11. The cell of claim 1, wherein said cell comprises a nucleic acid encoding said first chimeric protein.

12. The cell of claim 1, wherein said cell comprises a nucleic acid encoding said second chimeric protein.

13. The cell of claim 1, wherein

said nucleic acid encodes a GAL-4 binding site, and said effector gene is a reporter gene;

said first chimeric protein comprises a GAL-4 nucleic acid binding protein and a beta catenin or a Tcf; and

,

said second chimeric protein comprises a VP-16 and beta catenin or a Tcf.

14. The cell of claim 13, wherein said Tcf is Tcf4.

15. The cell of claim 1, wherein said cell further comprises a second nucleic acid encoding said ligand or metabolic product operably linked to an inducible promoter.

4. A cell comprising:

an accumulation or degradation of a metabolic product;

a nucleic acid encoding a peptide binding site and an effector gene;

a first chimeric protein comprising a nucleic acid binding protein that binds said peptide binding site where said nucleic acid binding protein is attached to said metabolic product or to a ligand that binds to said metabolic product; and

a second chimeric protein comprising an expression control protein attached to said metabolic product or to said ligand that binds to said metabolic product such that when said first chimeric protein comprises said metabolic product, said second chimeric protein comprises said ligand and when said first chimeric protein comprises said ligand, said second chimeric protein comprises said metabolic product;

wherein said expression control protein is a repressor.

16. A nucleic acid comprising a nucleic acid selected from the group consisting of

a nucleic acid encoding a chimeric protein comprising a nucleic acid binding domain attached to a Tcf4 or to a beta catenin, and

a nucleic acid encoding a transactivator attached to a beta catenin or to a Tcf4.

17. The nucleic acid of claim 16, wherein said nucleic acid comprises a nucleic acid encoding a nucleic acid binding domain attached to a Tcf4.

18. The nucleic acid of claim 16, wherein said nucleic acid comprises a nucleic acid encoding a nucleic acid binding domain attached to a beta catenin.

19. The nucleic acid of claim 16, wherein said nucleic acid comprises a nucleic acid encoding a Tcf4 attached to a transactivator.

20. The nucleic acid of claim 16, wherein said nucleic acid comprises a nucleic acid encoding a beta catenin attached to a transactivator.

21. The nucleic acid of claim 16, wherein said nucleic acid is a DNA.

22. The nucleic acid of claim 16, wherein said nucleic acid is a vector.

27. A kit for screening for an agent that modulates the ability of a cell to accumulate or to degrade a metabolic product, said kit comprising:

a container containing a nucleic acid of claim 16.

28. A kit for selectively killing a cell, said kit comprising a container containing a two-hybrid system component selected from the group consisting of:

a nucleic acid of claim 16, and

a protein encoded by a nucleic acid of claim 16.

23. A vector comprising:

a nucleic acid encoding a peptide binding site and an effector gene;

a nucleic acid encoding a first chimeric protein comprising a nucleic acid binding protein that binds said peptide binding site where said nucleic acid binding protein is attached to said metabolic product or to a ligand that binds to said metabolic product; and

a nucleic acid encoding a second chimeric protein comprising an expression control protein attached to said metabolic product or to said ligand that binds to said metabolic product such that when said first chimeric protein comprises said metabolic product, said second chimeric protein comprises said ligand and when said first chimeric protein comprises said ligand, said second chimeric protein comprises said metabolic product;

wherein said a nucleic acid encoding a first chimeric protein further encodes an HIV TAT domain attached to said first chimeric protein or;

wherein said a nucleic acid encoding a second chimeric protein further encodes an HIV TAT domain attached to said second chimeric protein.

24. A nucleic acid encoding a first chimeric protein comprising a nucleic acid binding protein attached to:

a metabolic product or to a ligand that binds to a metabolic product;

wherein said nucleic acid further encodes an HIV TAT domain attached to said first chimeric protein.

25. A nucleic acid encoding a second chimeric protein comprising an expression control protein attached to a metabolic product or to a ligand that binds to said metabolic product;

wherein said nucleic acid further encodes an HIV TAT domain attached to said first chimeric protein.

26. A kit for screening for an agent that modulates the ability of a cell to accumulate or to degrade a metabolic product, said kit comprising:

a container containing a mammalian cell comprising;

a nucleic acid encoding a protein binding site and an effector gene;

a first chimeric protein comprising a nucleic acid binding protein that binds said protein binding site attached to said metabolic product or to a ligand that binds to said metabolic product;

a second chimeric protein comprising an expression control protein attached to said metabolic product or to said ligand that binds to said metabolic product such that when said first chimeric protein comprises said metabolic product, said second chimeric protein comprises said ligand and when said first chimeric protein comprises said ligand, said second chimeric protein comprises said metabolic product.